ICL 670: A new oral chelator: A major breakthrough in treatment of thalassaemia

Indian Journal of Hematology and Blood Transfusion

Volumn 21, Issue 1, 2003, Pages

  Agarwal, M B ^a  

^a BOMBAY HOSPITAL   (India)

Author keywords

Chelator; ICL670; Iron; Thalassaemia

Indexed keywords

EID: 69249160558     PISSN: 09714502     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Galanello R: Iron chelation: New therapies. Semin Hematol 2001;38:73-76,
2. Giardina PJ, Grady RW. Chelation therapy in a-thalassaemia: The optimistic update. Semin Hematol 2001;38:360-366
3. Kushner JP, Porter JP, Olivieri NF: Secondary iron overload: Hematology: 2001;47-61.
4. Hoffbrand AV, Cohen A, Hershko C: Role of deferiprone in chelation therapy for transfusional iron overload: Blood: 2003 (First edition paper, pre-published online March 13).
5. Kontoghiorghes GJ,*Agarwal MB, Tondury P et al. Future of oral iron chelator deferiprone(Ll). ICOC Committee. Lancet 1993:341:1479.
6. Kontoghiorghes GJ, Agarwal MB, Grady RW et al. Deferiprone for thalassaemia. Lancet 2000;356:428-29.
7. Kontoghiorghes GJ, Agarwal MB, Tondury P et al. Deferiprone or fatal iron toxic effects? Lancet 2001;17:882-3
8. Agarwal MB, Gupte SS, Varandani D et al. Efficacy and safety of 1-2,dimethyl-3-hydroxypyride-4-one (LI) as an oral iron chelator in patients of#a-thalassaemia major with iron overload. J. Assoc. Phys. Ind. 1991;39:669-72
9. Agarwal MB, Gupte SS, Vishwanath C et al. Long-term assessment of efficacy a'nd safety of LI, an oral iron chelator, in transfusion'dependent thalassaemia: Indian trial. Br J Haematol. 1992;82:460-466.
10. Agarwal MB. Oral iron chelation: A review with special emphasis on • Indian work on deferiprone (LI). Ind. J Pediatr. 1993;60:509-16.
11. Agarwal MB. LI arthropathy syndrome. J Assoc Physicians India. 1994;42:929-30.
12. Agarwal MB. Oral iron chelators. Ind. Pediatr 1995;32:847-51.
13. Ponka P, Borova J, Neuwirth J, Fuchs O, Necas E. A study of intracellular iron metabolism using Pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta. 1979;586:278-297.
14. Richardson DR. Ponka P. Pyridoxal isonicotinoyl hydrazone & its analogs: Potential orally effective iron chelating agents for thetreat-ment of iron overload disease. J Lab Clin Med. 1998;131:306-314.
15. Becker E, Richardson DR. Development of novel aroylhydrazone ligands for iron chelation therapy. 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. J Lab Clin Med 1999;134:510-521.
16. Hershko C, Grady RW, Link G. Phenolic ethylenediamine derivatives: A study of orally effective iron chelators. J Lab Clin Med. 1984;103:337-346.
17. Grady RW, Salbe AD, Hilgartner MW, Giardina PJ. Results from a phase I clinical trial of HBED. Adv Exper Med Biol. 1994;356:351
18. Grady RW, Giardina PJ. Oral iron chelators: A potential role for HBED in combination therapy (Abstract) Blood 1999;94:3293a.
19. Schnebli HP. CGP 72 670, a new potent, orally active iron chelator (abstract). ISH-EHA Combined Haematology Congress, Amsterdam. The Netherlands. Br J Haematol. 1998;102:0-1121a.
20. Piga A, Galanello R, Dessi C, et al. A novel oral iron chelator (ICL670) results of a phase-I single- dose safety study. Blood 1999;94:3304a.
21. Nick HP, Acklin P, Faller B, et al. ICL 670: a new potent, orally active iron chelator. In: Bergeron R, Badman D, Brittenham G.eds. Iron chelators: New Development Strategies. Ponte Vedra, FL Saratoga Publishers: 2000;311-331.
22. Hershko C, Konijn AM, Nick HP et al. ICL 670: A new synthetic oral chelator: Evaluation in hypertransfused rats with selective radio-iron probes of hepatocellular and reticulo-endothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001;97:1115-1122.
23. Nishbet-Brown E, Oliviei NF, Giardina PJ et al. ICL 670, A tridentate orally-active iron chelator, provides net negative iron balance and increased serum iron binding capacity in iron overloaded patients with thalassaemia. Abstract No. 3111, 44th Annual ASH meeting, Philadelphia, December, 2002.
24. Piga A, Galanello R, Cappelini MD et al. Phase-II study of oralchelator ICL670 in thalassaemia patients with transfusional iron overload: Efficacy, safety, pharmacokinetics and pharmacodynamics after 6 months of therapy. Abstract No. 5, 44th Annual ASH meeting, Philadelphia, December, 2002 (Abstract: Blood: 2002; 100:5a).
25. Grady RW, Berdoukas V, Rachmilewitz EA et al. When deferiprone and desferoxamine are combined, iron excretion is enhanced. Abstract No. 2060, 44th Annual ASH meeting, Philadelphia, December, 2002.
26. Hershko C, Link G, Konijn AM et al. Combined treatment with pyridoxal isonicotinoyl hydrazone (PIH) analogs and deferoxamine produces a shuttle effect improving chelating response. Abstract No. 15, 44th Annual ASH meeting, Philadelphia, December, 2002
27. Grady RW, Berdoukas VA, Rachmilewitz EA et al. Combinations of desferrioxamine and deferiprone markedly enhance iron excretion. Abstract 911. 44th Annual ASH meeting, Philadelphia, December, 2002.